

Registry Number (Country)	Title	Cancer Origin	Status	Study Type	Protocol
NA (Germany)	Second line chemotherapy combined sequentially with PIPAC for peritoneal metastasis in gastric cancer: a randomized phase-II trial (PMGA-PIPAC)	GA	Grant Application Pending	Phase II	NA
NCT03868228 (United Kingdom)	Pilot Study Assessing the Efficacy of Oxaliplatin Based Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the Treatment of Colorectal Peritoneal Metastases	CR	Recruiting	Phase II	PIPAC cycles of Oxaliplatin +/- concomitant systemic chemotherapy
NCT03875144 (France)	Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)	MM	Not Yet Recruiting	Phase II	4x PIPAC cycles of Cisplatin 10.5mg/m ² + Doxorubicin 2.1 mg/m ² + systemic chemotherapy (Cisplatin 75mg/m ² + Pemetrexed 500mg/m ²) at 6 week intervals vs. 6 systemic chemotherapy
EudraCT: 2018-003664-31 (France, Italy, Germany)	PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intraperitoneal Chemotherapy (PIPAC) vs. Chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer	OV, FT, PP	Recruiting	Phase III	3x PIPAC cycles of Cisplatin + Doxorubicin at 6 week intervals without systemic chemotherapy vs. systemic chemotherapy alone (physician's best choice of pegylated liposomal Doxorubicin or Topotecan or Gemcitabine or Paclitaxel weekly +/- Bevacizumab
CTRI: 2018/08/02122	Pressurized Intraperitoneal Aerosol	OV	Recruiting	Phase III	3x PIPAC cycles of Cisplatin 10.5mg/m ² + Doxorubicin

3 (India)	Chemotherapy vs Intravenous Chemotherapy for Unresectable Peritoneal Metastases secondary to Platinum resistant Ovarian cancer – A Randomized control Trial				2.1mg/m ² at 6 week intervals vs. 6 cycles of liposomal Doxorubicin/Gemcitabine/Paclitaxel/Nab Paclitaxel/Topotecan at 3 week intervals
Retrospectively registered	PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study	GA	Recruiting	Phase II	3x PIPAC Cisplatin 10.5mg/m ² + Doxorubicin 2.1mg/m ² + systemic chemotherapy vs. systemic chemotherapy alone
CRTI: 2018/08/02122 5 (India)	Randomized control trial comparing quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and intravenous chemotherapy	Mixed	Recruiting	QoL RCT	3x PIPAC cycles vs. 6x cycles of systemic chemotherapy
EudraCT: 2018-001035-40 (Germany, Switzerland)	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding - A phase II/III trial of the AIO/CAOGI/ACO	Upper GI (EG), BD, PA, GA)	Recruiting	Phase III	3x PIPAC cycles + 9x cycles of mFOLFOX6 vs. 12x cycles of mFOLFOX6
NCT03304210 (Belgium)	Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer (PIPAC-nabpac)	GA, PA, BR, OV	Recruiting	Phase I	3x PIPAC cycles of Abraxane 35-140 mg/m ² at 4 week intervals (dose escalation)

NCT03294252 (France)	Phase I / II Dose Escalation of Oxaliplatin Via a Laparoscopic Approach of Aerosol Pressurized Intraperitoneal Chemotherapy for Nonresectable Peritoneal Metastases of Digestive Cancers (PIPOX)	GA, SB, CR	Recruiting	Phase I/II	PIPAC cycles of Oxaliplatin 90-300mg/m2 (dose escalation) + 5-Fluorouracil + L-Folinic acid
NCT03287375 (Denmark)	Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol - The PIPAC-OPC2 Trial	OV, CR, AP, PP	Recruiting	Phase II	CR or AP: PIPAC cycles of Oxaliplatin 92 mg/m2 in 150 ml dextrose. Other GI or GYN: PIPAC cycles of Cisplatin 7.5 mg/m2 in 150 ml saline + Doxorubicin 1.5 mg/m2 in 50 ml saline at 3-5 week intervals
NCT03280511 (Denmark)	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients - The PIPAC-OPC3 CC Trial	CR	Recruiting	Phase II	2 months s/p colon resection (or adjuvant systemic chemotherapy, if indicated): PIPAC cycles of oxaliplatin 92 mg/m2 at 5 week intervals.
NCT03246321 (Netherlands)	Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC)	CR, AP	Recruiting	Phase II	ePIPAC cycles of Oxaliplatin 92 mg/m2 + SC with Leucovorin (20 mg/m2) + 5-Fluorouracil (400 mg/m2) at 6 week intervals
NCT03172416 (Singapore)	Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis	GA	Unknown	Phase I	PIPAC cycles of Oxaliplatin 45-150 mg/m2 (dose escalation)
NCT02735928 (Italy)	Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol	OV	Recruiting	Phase I/II	PIPAC cycles of Cisplatin 7.5mg/m2 + Doxorubicin 1.5mg/m2 at 4-6 week intervals

	Chemotherapy (PIPAC) With Cisplatin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase I-II Clinical Trial (PARROT)				
NCT02604784 (Italy)	Feasibility, Efficacy and Safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) With Oxaliplatin, Cisplatin and Doxorubicin in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancers and Primary Tumors of the Peritoneum: An Open-label, Two-arms, Phase I-II Clinical Trial. (PI-CaP)	CR, OV, GA, PP	Recruiting	Phase I/II	PIPAC cycles of Cisplatin 7.5-100 mg/m ² + Doxorubicin 1.5-30 mg/m ² or Oxaliplatin 92-300 mg/m ² (dose escalation)